Agios Pharmaceuticals, Inc.

BMV:AGIO * Stock Report

Market Cap: Mex$65.0b

Agios Pharmaceuticals Valuation

Is AGIO * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGIO * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AGIO * (MX$983.02) is trading below our estimate of fair value (MX$3325.66)

Significantly Below Fair Value: AGIO * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGIO *?

Key metric: As AGIO * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AGIO *. This is calculated by dividing AGIO *'s market cap by their current earnings.
What is AGIO *'s PE Ratio?
PE Ratio4.7x
EarningsUS$674.31m
Market CapUS$3.18b

Price to Earnings Ratio vs Peers

How does AGIO *'s PE Ratio compare to its peers?

The above table shows the PE ratio for AGIO * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.1x
6446 PharmaEssentia
105x92.0%NT$193.7b
PTGX Protagonist Therapeutics
16.2x-31.4%US$2.8b
4587 PeptiDream
21.3x-9.2%JP¥364.1b
CPRX Catalyst Pharmaceuticals
17.9x17.5%US$2.6b
AGIO * Agios Pharmaceuticals
4.7x-56.7%Mex$3.2b

Price-To-Earnings vs Peers: AGIO * is good value based on its Price-To-Earnings Ratio (4.7x) compared to the peer average (39.3x).

Price to Earnings Ratio vs Industry

How does AGIO *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

19 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a0%
AGIO * Agios Pharmaceuticals
 4.7x-56.7%US$3.18b
No. of Companies20PE020406080100+
19 CompaniesEstimated GrowthMarket Cap
Industry Avg.n/a0%
AGIO * Agios Pharmaceuticals
 4.7x-56.7%US$3.18b
No more companies

Price-To-Earnings vs Industry: AGIO * is good value based on its Price-To-Earnings Ratio (4.7x) compared to the Global Biotechs industry average (25.2x).

Price to Earnings Ratio vs Fair Ratio

What is AGIO *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGIO * PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AGIO *'s Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV *

US$3,880.00

7D

-11.8%

1Y

12.0%

CSPC Pharmaceutical Group

HK$69.4b

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.

1093 N

HK$15.69

7D

0%

1Y

-27.0%

Exact Sciences

US$13.1b

Provides cancer screening and diagnostic test products in the United States and internationally.

EXAS *

US$872.00

7D

0%

1Y

n/a